chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Listless, Night sweats, Vaccination site pain
Clinical narrative: Had been perspiring profusely in my sleep; That night I had a mild night sweat again but very slight.; Soreness at injection site; Felt somewhat listless at work; Before bedtime felt slight chill. My clothing being damp from work.; This is a spontaneous report from a contactable consumer, the patient. A 68-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the right arm on 26Feb2021 at 10:00 (at the age of 68-year-old), as a single dose for COVID-19 immunisation. Medical history included allergy to pollen, mold and plants and some mild food allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 26Feb2021, patient felt slight chill before bedtime and patient's clothes were damp from work. The patient had no problem sleeping. On 27Feb2021 at 03:00, the patient was perspiring profusely in sleep. The patient checked temperature and was quite normal so changed clothes and went back to sleep. On 27Feb2021, patient experienced normal soreness at injection site and felt somewhat listless at work. That night patient had a mild night sweat again but very slight. The patient had nothing like that currently and felt great. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the events slight chill, perspiring profusely in sleep/ mild night sweat again but very slight, soreness at injection site and felt somewhat listless at work was recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea, Vaccination site erythema, Vaccination site swelling
Clinical narrative: Nauseated; Fatigue; Headache; Arm where shot was given red; Arm where shot was given swollen; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the right arm on 23Feb2021 at 14:00 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma, prediabetes, gout, hypertension, obstructive sleep apnea and sulpha drugs allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications taken within two weeks included atenolol (MANUFACTURER UNKNOWN), budesonide/formoterol fumarate (SYMBICORT), folic acid (MANUFACTURER UNKNOWN), vitamin b12 (CYANOCOBALAMIN) and multivitamin (MANUFACTURER UNKNOWN); all for unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Em9810) via an unspecified route of administration in the right arm on 02Feb2021 at 15:15 (at the age of 64-year-old) as a single dose for COVID-19 immunisation. The patient previously also received allopurinol (MANUFACTURER UNKNOWN) and ciprofloxacin (MANUFACTURER UNKNOWN) and experienced allergy to the medications. On 24Feb2021 at 01:00, the patient experienced nauseated, fatigue, headache, arm where shot was given red and swollen. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care.. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nauseated, fatigue and headache was resolved on an unknown date in Feb2021, after the duration of 72 hours, while arm where shot was given red and swollen was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Skin disorder
Clinical narrative: Non itchy pink bumps all over body; This is a spontaneous report from a contactable consumer. A 66-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1283) via an unspecified route of administration in the left arm on 18Feb2021 at 10:30 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure and acid reflux. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN), acetylsalicylic acid (ASPIRIN) and multivitamin (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Feb2021, the patient experienced small non itchy pink bumps all over body, the patient started noticing them on legs two days post vaccination and didn't think anything of it. On 26Feb2021, eight days post vaccination, the patient noticed more bumps on arms and stomach. The bumps were not painful, itchy, or threatening in any way, just slightly alarming that they were there. It was also reported that the reporter was unsure if it was a side effect of the COVID vaccine. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event small non itchy pink bumps all over body was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Disorientation, Dizziness, Fatigue, Migraine, Vomiting
Clinical narrative: Vomiting; dizziness; extreme fatigue; disoriented; migraine; This is a spontaneous report from a non-contactable consumer, the patient. A 32-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 15Feb2021 at 11:00 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included depression, anxiety and hypothyroidism. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levonorgestrel (MIRENA), sertraline hydrochloride (ZOLOFT) and levothyroxine (MANUFACTURER UNKNOWN); all from an unknown date and unknown if ongoing for an unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccination. The patient previously received codeine on an unknown date and experienced allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation and did not experience any side effects. On 16Feb2021 at 06:00, the patient experienced vomiting, dizziness, migraine, extreme fatigue. It was reported that on the same day about 20 hours after the vaccination, the patient couldn't move her body out of her bed and her husband helped the patient to the bathroom where the patient threw up multiple times and slept for about 4 hours. On the same day, following the sleep when she opened her eyes, the patient felt very dizzy and disoriented and even had migraines for 2-3 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vomiting, dizziness, migraine, extreme fatigue and disoriented was resolved on an unknown date in Feb2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vomiting
Clinical narrative: Nausea; Throwing up; This is a spontaneous report from a contactable healthcare professional, the patient. A 22-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm left on 03Mar2021 (at the age of 22-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication included tri lo sprintec (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 03Mar2021 at 23:30, the patient experienced nausea and throwing up. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea and vomiting was resolving at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: she noticed she was scratching under her breasts and around on her back. Her son and she checked. There was no apparent rash. No other symptoms. It was 3 AM and she just woke up scratching the area again.; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 03Mar2021 (at the age of 71-year-old) at 15:15 as a single dose for COVID-19 immunisation. Medical history included gastroesophageal reflux disease (GERD), osteoarthritis, high cholesterol, thyroid cancer and removal, gallbladder removal, hysterectomy and nickel allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included omeprazole (MANUFACTURER UNKNOWN), fenofibrate (MANUFACTURER UNKNOWN), levothyroxine sodium (LEVOXYL) and pramipexole (MANUFACTURER UNKNOWN); all taken for an unknown indication, from an unknown date and unknown if ongoing. The patient previously received diflucan (MANUFACTURER UNKNOWN) and experienced drug allergy. On 03Mar2021 at 20:00, about 5 or 6 hours after the vaccination, the patient noticed that she was scratching under her breasts and around on her back. She and her son checked that there was no apparent rash and no other symptoms. It was 03:00 and she just woke up scratching the area again (pruritus). It was burning so she applied a cold wet cloth and it settled quickly. The patient had messaged her physician with this information also and she was not concerned at all. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event pruritus was recovered on 04Mar2021.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Severe swelling & pain in lymph node in arm pit; Severe swelling & pain in lymph node in arm pit; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration on 02Mar2021 at 16:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications included amoxicillin (MANUFACTURER UNKNOWN), vitamin b nos (MANUFACTURER UNKNOWN) and ascorbic acid, herbal nos, levoglutamide, lysine, magnesium, manganese, retinol, riboflavin, selenium, tocopherol, zinc (AIRBORNE); all for unknown indication from an unknown date and unknown if ongoing. On 03Mar2021, the patient experienced severe swelling & pain in lymph node in arm pit. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe swelling & pain in lymph node in arm pit was unknown at the time of this report.    No follow-up attempts are needed. No further information is expected
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Hypoaesthesia, Pain in extremity, Vaccination site erythema
Clinical narrative: Diarrhea day 2 through day 3; Left arm soreness; Left arm numbness; Redness near injected area; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 01Mar2021 at 16:30 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism and Chiari. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Mar2021 at 20:00, the patient experienced diarrhea day 2 through day 3, left arm soreness and numbness and redness near injected area. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event diarrhea was recovered on 03Mar2021; while that of the events left arm soreness and numbness and redness near injected area was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Nausea, Vaccination site discomfort, Vertigo
Clinical narrative: vertigo -- feels like motion sickness and when "I" lie down the ceiling appears to be spinning; Slight discomfort at the location of the shot (left arm); Nausea; Headache; This is a spontaneous report from a contactable consumer, the patient. A 72-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 03Mar2021 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. Medical history included parkinsonism, diabetes, sleep apnea, fatty liver, autoimmune disorder unknown high rheumatoid arthritis (RA) factor and positive antinuclear antibodies (ANA), penicillin allergy and latex allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included carbidopa/levodopa (MANUFACTURER UNKNOWN), acetylsalicylic acid (ASPIRIN), fish oil (OMEGA 3) and multiple vitamin (MANUFACTURER UNKNOWN); all for unknown indication from an unknown dates and unknown if ongoing. The patient previously received primidone (MANUFACTURER UNKNOWN) and rotigotine (NEUPRO PATCH) both for an unknown indication from an unknown dates and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 10Feb2021 at 14:45 (at the age of 72-year-old) as a single dose for COVID-19 immunisation. On 04Mar2021 at 04:30, the patient experienced vertigo which felt like motion sickness and when she lied down the ceiling appears to be spinning, nausea, headache slight and discomfort at the location of the shot (left arm). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vertigo, slight discomfort at the location of the shot (left arm), nausea and headache were not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Extreme vertigo for 36 hours, lingering vertigo for 5 days; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9266) via an unspecified route of administration in the left arm on 24Feb2021 at 09:45 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included opioid allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included vitamin d (MANUFACTURER UNKNOWN) and ascorbic acid (VITAMIN C); both for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Feb2021 at 17:30, the patient experienced extreme vertigo for 36 hours and lingering vertigo for 5 days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme vertigo for 36 hours and lingering vertigo for 5 days was recovered on an unknown date in 2021.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain
Clinical narrative: Chills; Headache; Deep body aches; Fatigie; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 27Feb2021 at 11:00 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included osteoarthritis and fibromyalgia. Concomitant medication included levothyroxine, liothyronine (NP THYROID); taken for unknown indication from an unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Mar2021 at 12:00, the patient experienced chills, headache, deep body aches and "fatigie". The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, headache, deep body aches and "fatigie" were not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site rash
Clinical narrative: Rash and soreness at injection site; Rash and soreness at injection siteafter second injection; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the arm right on 01Mar2021 at 09:30 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included diverticulitis and glaucoma suspect. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and dorzolamide, timolol maleate (DORZOLAMIDE; TIMOLOL MALEATE); both for unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9809) via an unspecified route of administration in the arm right on 08Feb2021 at 14:30 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. On 03Mar2021 at 07:00, the patient experienced rash and soreness at injection site. No therapeutic measures were taken as a result of the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of rash and soreness at injection site was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Dyspepsia, Fatigue, Flatulence, Frequent bowel movements
Clinical narrative: Gas; Heart burn; Abdominal discomfort; Frequent bowel movements; Sick; Nauseous; General feeling of being tired; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EN5318) via an unspecified route of administration in the left arm on 22Feb2021 at 11:45 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis, high blood pressure, IBS (irritable bowel syndrome) and known allergies to penicillin. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included indapamide (MANUFACTURER UNKNOWN), celecoxib (MANUFACTURER UNKNOWN), anastrozole (MANUFACTURER UNKNOWN) and acetylsalicylic acid (BABY ASPIRIN); all for an unknown indication from an unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EN5318) via an unspecified route of administration in the left arm on 01Feb2021 at 11:45 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. On 23Feb2021, the patient experienced nauseous, gas, heart burn, abdominal discomfort, frequent and urgent bowl movements, general feeling of being tired and sick. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of reported events which included bland diet and pepcid started from an unknown date. The clinical outcome of the events nauseous, gas, heart burn, abdominal discomfort, frequent and urgent bowl movements, general feeling of being tired and sick were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Illness, Nausea
Clinical narrative: Gas; Heart burn; Abdominal discomfort; Frequent bowel movements; Sick; Nauseous; General feeling of being tired; This is a spontaneous report from a contactable consumer, the patient. A 75-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EN5318) via an unspecified route of administration in the left arm on 22Feb2021 at 11:45 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis, high blood pressure, IBS (irritable bowel syndrome) and known allergies to penicillin. Prior to vaccination, the patient was not diagnosed with COVID -19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included indapamide (MANUFACTURER UNKNOWN), celecoxib (MANUFACTURER UNKNOWN), anastrozole (MANUFACTURER UNKNOWN) and acetylsalicylic acid (BABY ASPIRIN); all for an unknown indication from an unknown dates and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE: Lot Number: EN5318) via an unspecified route of administration in the left arm on 01Feb2021 at 11:45 (at the age of 75-years-old) as a single dose for COVID-19 immunisation. On 23Feb2021, the patient experienced nauseous, gas, heart burn, abdominal discomfort, frequent and urgent bowl movements, general feeling of being tired and sick. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of reported events which included bland diet and pepcid started from an unknown date. The clinical outcome of the events nauseous, gas, heart burn, abdominal discomfort, frequent and urgent bowl movements, general feeling of being tired and sick were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Left axillary lymphadenopathy.; This is a spontaneous report from a contactable consumer, the patient. A 26-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6205) via an unspecified route of administration in the left arm on 02Mar2021 at 08:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL 9264) via an unspecified route of administration in the left arm on 10Feb2021 at 08:00 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was not reported whether the patient received any other vaccines within four weeks prior to the vaccination. On 03Mar2021 at 12:00, the patient experienced left axillary lymphadenopathy. Therapeutic measures were not taken as a result of the event. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left axillary lymphadenopathy was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Swelling
Clinical narrative: Swollen and pain in left armpit area; Swollen and pain in left Armpit area; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 02Mar2021 at 11:45 (at the age of 55-year-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9265) via an unspecified route of administration in the left arm on 09Feb2021 at 12:45 (at the age of 55-year-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 03Mar2021 at 08:00, the patient experienced swollen and pain in left armpit area. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events swollen and pain in left armpit area were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: M
Vaccine: COVID19
Symptoms: Abnormal dreams, Fatigue, Pain in extremity, Restlessness
Clinical narrative: Left arm soreness throughout the day; Tiredness in the evening; Restlessness during the night; Had unusual dreams; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in left arm on 03Mar2021 at 09:30 (at the age of 42-years old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not have any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 10Feb2021 at 09:15 (at the age of 42-years old) as a single dose for COVID-19 immunisation. On 03Mar2021 at 18:00, the patient experienced left arm soreness throughout the day, tiredness in the evening and restlessness in the night. The patient also had unusual dreams. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events left arm soreness throughout the day, tiredness in the evening, restlessness during the night and had unusual dreams was recovering at the time of report.  No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain, Pain in extremity
Clinical narrative: Nausea; Body aches; Severe muscle/body ache in left arm; This is a spontaneous report from a contactable consumer. A 77-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6200) via an unspecified route of administration in the left arm on 03Mar2021 at 14:00 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes, heart failure and spinal stenosis. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received other concomitant medications within two weeks of the vaccination which are unspecified. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the left arm on 10Feb2021 at 13:30 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. On 04Mar2021 at 03:00, the patient experienced nausea, body aches and severe muscle/body ache in left arm. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events nausea, body aches and severe muscle/body ache in left arm was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 78-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Mar2021 at 10:30 (at the age of 78-years-old) as a single dose for COVID-19 immunisation. Medical history included arthritis.  The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, the patient experienced dizziness. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event dizziness was not resolved at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Insomnia, Tremor
Clinical narrative: Towards the end of the 5 hours "I" also experienced mild chills. "I" have never experienced this before; On the day of taking the vaccine when "I" went to bed my body started shaking uncontrollably.; "I" was unable to sleep; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 03Mar2021 at 10:45 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included mild hypertension. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1283) via an unspecified route of administration in the left arm on 10Feb2021 at 11:00 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. On 03Mar2021 at 23:00, the patient went to bed and his body started shaking uncontrollably. This lasted for 5 hours and the patient was unable to sleep. 04Mar2021, towards the end of the 5 hours, the patient experienced mild chills. The patient had never experienced this before. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events shaking uncontrollably was resolved after 5 hours on 04 Mar2021 at 04:00; while that of the events mild chills and unable to sleep was recovered on 04Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Extreme vertigo; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Mar2021 at 16:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included meniere's disease, hypothyroidism and high blood pressure. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19.  The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC), sertraline (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN); all were taken for an unknown indication from an unknown date and unknown if ongoing. On 03Mar2021 at 11:00 (also reported lasted for 6 hours), the patient experienced extreme vertigo and had to lay down on the floor at work and it lasted about 6 hours. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event which included treatment with unspecified decongestant and fever reducer. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event extreme vertigo was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness
Clinical narrative: Tightness in neck; This is a spontaneous report from a contactable nurse, the patient. A 71-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6205) via an unspecified route of administration in the left arm on 03Mar2021 at 14:30 (at the age of 71-year-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism, gastroesophageal reflux disease (GERD), arthritis and chronic back pain. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included levothyroxine sodium (LEVOTHYROXIN), gabapentin (MANUFACTURER UNKNOWN) and famotidine (PEPCID); all from an unknown dates for an unknown indication and unknown if ongoing. The patient previously received codeine (MANUFACTURER UNKNOWN) and morphine (MANUFACTURER UNKNOWN) for an unknown indication on an unknown date and experienced severe nausea. On 03Mar2021 at 23:00, the patient experienced tightness in neck. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event neck tightness was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness
Clinical narrative: Dizziness that required to crawl to bed; Not a lot of energy; This is a spontaneous report from a contactable consumer, the patient. A 66-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Feb2021 at 09:15 (at the age of 66-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history or any known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Concomitant medications included ropinirole (MANUFACTURER UNKNOWN) and an unspecified stool softener; both taken for unspecified indications from unknown dates and unknown if ongoing. On 25Feb2021 at 21:00, after 12 hours of having no side effects, the patient experienced dizziness that required him to crawl to bed. When he laid down or crawled on all fours, he was ok and the next day also he was ok. The dizziness had subsided. The last 5 days, he had no dizziness. On an unknown date in Feb2021, the patient had not had a lot of energy. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the dizziness was recovered in 2021; while that of the patient had not had a lot of energy was recovering.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Left arm lymph node pain; Left arm lymph node pain and swelling; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 02Mar2021 at 10:15 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date and unknown if ongoing. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included desvenlafaxine succinate monohydrate (PRISTIQ), taken for unknown indication from an unknown date and unknown if ongoing. On 03Mar2021, the patient experienced left arm lymph node pain and swelling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events left arm lymph node pain and swelling was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Acne
Clinical narrative: This is a spontaneous report from a non-contactable consumer (the patient). A 24-year-old female patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 24, via an unspecified route of administration, in the right arm, on an unknown date, in Feb 2021, single dose, for COVID-19 immunisation. No medical history or concomitant medications reported. The patient has no known allergies to medications, food or other products. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. On an unknown date in Feb 2021, patient experienced mild acne breakouts on upper back and chest. Since the vaccination, patient has not tested for COVID-19. The outcome of mild acne breakouts on upper back and chest: unknown (at the time of report). No follow-up attempts possible. Information about lot/batch number cannot be obtained. No further information expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity
Clinical narrative: Sore arm; Tiredness; Minor headache; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 03Mar2021 at 11:30(at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfonamide allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior the COVID vaccine. Concomitant medications were not reported. On 03Mar2021 at 13:30, the patient experienced sore arm, tiredness, headache. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the event sore arm, tiredness, headache was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Soreness at the injection site if pressed; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 25Feb2021 at 15:15 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient received birth control(unspecified) and allergy medicine (unspecified) within two weeks of vaccination. On 26Feb2021, the patient experienced soreness at the injection site if pressed. The adverse event did not result in doctor/other health care professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event soreness at the injection site if pressed was resolved on an unknown date in Feb2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Taste disorder
Clinical narrative: Change in taste; This is a spontaneous report from a contactable nurse, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 26Feb2021 at 11:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications included minerals nos/vitamins nos (PRENATAL VITAMINS) for an unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Feb2021 at 12:00, the patient experienced change in taste. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event change in taste was not recovered at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.